TY - JOUR
T1 - Hyperthermia generated by magnetic nanoparticles for effective treatment of disseminated peritoneal cancer in an orthotopic nude-mouse model
AU - Matsumi, Yuki
AU - Kagawa, Tetsuya
AU - Yano, Shuuya
AU - Tazawa, Hiroshi
AU - Shigeyasu, Kunitoshi
AU - Takeda, Sho
AU - Ohara, Toshiaki
AU - Aono, Hiromichi
AU - Hoffman, Robert M.
AU - Fujiwara, Toshiyoshi
AU - Kishimoto, Hiroyuki
N1 - Funding Information:
This work was supported by the JSPS KAKENHI [JP19K07730]; JSPS KAKENHI [JP15K09959]. We thank Dr. Takeshi Nagasaka for helpful discussions, and Tae Yamanishi and Tomoko Sueishi for their excellent technical support.
Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - Magnetic hyperthermia (MHT), which combines magnetic nanoparticles (MNPs) with an alternating magnetic field (AMF), holds promise as a cancer therapy. There have been many studies about hyperthermia, most of which have been performed by direct injection of MNPs into tumor tissues. However, there have been no reports of treating peritoneal disseminated disease with MHT to date. In the present study, we treated peritoneal metastasis of gastric cancer with MHT using superparamagnetic iron oxide (Fe3O4) nanoparticle (SPION) coated with carboxydextran as an MNP, in an orthotopic mouse model mimicking early peritoneal disseminated disease of gastric cancer. SPIONs of an optimal size were intraperitoneally administered, and an AMF (390 kHz, 28 kAm−1) was applied for 10 minutes, four times every three days. Three weeks after the first MHT treatment, the peritoneal metastases were significantly inhibited compared with the AMF-alone group or the untreated-control group. The results of the present study show that MHT can be applied as a new treatment option for disseminated peritoneal gastric cancer. Abbreviations: AMF: alternating magnetic field; Cy1: cytology-positive; DMEM: Dulbecco’s Modified Eagle’s Medium; FBS: fetal bovine serum; H&E: hematoxylin and eosin; HIPEC: hyperthermic intraperitoneal chemotherapy; MEM: Minimum Essential Medium; MHT: magnetic hyperthermia; MNPs: magnetic nanoparticles; P0: macroscopic peritoneal dissemination; RFP: red fluorescent protein; SPION: superparamagnetic iron oxide (Fe3O4) nanoparticle.
AB - Magnetic hyperthermia (MHT), which combines magnetic nanoparticles (MNPs) with an alternating magnetic field (AMF), holds promise as a cancer therapy. There have been many studies about hyperthermia, most of which have been performed by direct injection of MNPs into tumor tissues. However, there have been no reports of treating peritoneal disseminated disease with MHT to date. In the present study, we treated peritoneal metastasis of gastric cancer with MHT using superparamagnetic iron oxide (Fe3O4) nanoparticle (SPION) coated with carboxydextran as an MNP, in an orthotopic mouse model mimicking early peritoneal disseminated disease of gastric cancer. SPIONs of an optimal size were intraperitoneally administered, and an AMF (390 kHz, 28 kAm−1) was applied for 10 minutes, four times every three days. Three weeks after the first MHT treatment, the peritoneal metastases were significantly inhibited compared with the AMF-alone group or the untreated-control group. The results of the present study show that MHT can be applied as a new treatment option for disseminated peritoneal gastric cancer. Abbreviations: AMF: alternating magnetic field; Cy1: cytology-positive; DMEM: Dulbecco’s Modified Eagle’s Medium; FBS: fetal bovine serum; H&E: hematoxylin and eosin; HIPEC: hyperthermic intraperitoneal chemotherapy; MEM: Minimum Essential Medium; MHT: magnetic hyperthermia; MNPs: magnetic nanoparticles; P0: macroscopic peritoneal dissemination; RFP: red fluorescent protein; SPION: superparamagnetic iron oxide (Fe3O4) nanoparticle.
KW - Hyperthermia
KW - disseminated cancer
KW - gastric cancer
KW - magnetic nanoparticles
KW - milky spot
KW - nude mice
KW - orthotopic
UR - http://www.scopus.com/inward/record.url?scp=85107794680&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107794680&partnerID=8YFLogxK
U2 - 10.1080/15384101.2021.1919441
DO - 10.1080/15384101.2021.1919441
M3 - Article
C2 - 34110969
AN - SCOPUS:85107794680
SN - 1538-4101
VL - 20
SP - 1122
EP - 1133
JO - Cell Cycle
JF - Cell Cycle
IS - 12
ER -